Key Takeaways
- Strong quarter, broad-based beat: US revenue hit a record $195 mn (+30% YoY) and One India grew double digits for the seventh straight quarter, driving gross margin up 450 bps YoY to 65.5%.
- The US engine is firing on all cylinders: Respiratory and peptide franchises are scaling, lenalidomide remains a material contributor, and the pipeline promises Advair, Abraxane and another peptide within 15 months.
- South Africa is the one soft spot: SAGA missed internal estimates as supply chains reconfigure post-COVID, but management called the bottom and expects normalization from Q1 next fiscal.
- Margins are peaking, not plateauing: Q3 benefited from seasonality, mix and forex; Q4 will moderate. Full-year EBITDA margin guidance of 21–22% is intact, with a stated intention to grow margins year-on-year while reinvesting for faster growth.
- What to watch next quarter: The Advair approval decision in early April, the trajectory of South Africa's recovery, and whether the US base can hold above the $185–190 mn guided floor as Q4 seasonality kicks in.
US Formulations: Record Quarter & Pipeline Catalyst
- Record revenue: The US business delivered its highest-ever quarterly revenue at $195 mn, marking the tenth consecutive quarter of growth and a 30% YoY increase.
- Lenalidomide: Sales were marginally lower QoQ but the product remains a material contributor. Management believes the market will remain undersupplied by generics for the next one to two years, muting competitive intensity and price erosion relative to a typical generic.
- Lanreotide: Market share reached 14.1% as of November 2022, steadily gaining. The trajectory is in line with expectations; further share expansion is possible but will not come in a single large jump given the product's nature.
- Leuprolide depot: Launched during the quarter, expanding the peptide franchise. The ramp is expected to be slower than a regular generic, similar to lanreotide, given multiple brands already in the market.
- Respiratory portfolio: Generic market shares expanded over the last twelve months, supported by sustainable supplies and a competitive cost position. Albuterol pricing saw no meaningful change QoQ.
- Advair catalyst: Cipla responded to a minor query letter; the new target action date is the first week of April. Management believes the site inspection is complete and feels closer to an approval than before, though a reinspection of Indore is not ruled out.
- Pipeline visibility: Beyond Advair, the next 15 months include Abraxane (potential launch in the second half of H2 FY24) and one additional peptide product by September. A few other products exist but timing is uncertain due to FDA correspondence.
- Medium-term ambition: From a current ~$700 mn 12-month run rate, management sees a line of sight to reach $900 mn over time, with an active pipeline build beyond that.
Vohra: "Our target action date is hopefully in the first week of April. So I think we are quite looking forward to being able to bring the product to the market and it's the first week of April."
One India: Consistent Market-Beating Growth
- Seventh consecutive quarter of outperformance: Branded prescription business grew 11%, significantly ahead of the market, driven by a healthy mix of price, volume and new launches.
- Chronic therapies lead: Respiratory, cardiac and anti-diabetic therapies all outperformed the market. Chronic now represents 60% of the prescription business and grew double digits; respiratory alone grew ~17%.
- Trade generics: Strong volume traction continued, with steady order flow from Tier 2 to Tier 6 rural towns and demand fulfillment across regions, strengthening Cipla's leadership position.
- Consumer franchise: On track to reach nearly Rs. 1,100 crores by the end of this fiscal year.
- Growth outlook: Management expects growth to remain higher than the market, consistent with the trajectory of the past seven to eight quarters.
International Markets: SAGA Drag, DTM Resilience
- SAGA underperformance: South Africa private business came in lower than internal estimates this quarter, driven by a post-COVID reconfiguration of supply chains. Customer stock levels are falling as the supply chain adjusts, and overall market growth has shrunk.
- The bottom call: Management stated the worst is probably in the numbers over the last two quarters and expects a resumption to normal from Q1 of next fiscal. Supply issues should resolve from next year onwards, making the benefits of above-market growth more visible.
- DTM markets: Reported dollar numbers were pressured by depreciating local currencies against the US dollar, but this masked healthy double-digit secondary growth across markets.
- Broader EM caution: Economies in Europe and South Africa are responding to the global situation; self-pay markets remain sensitive to economic conditions. Management continues to monitor geopolitical headwinds that have ebbed but persist.
Vohra: "So my guess is this is the worst is probably in our numbers over the last two quarters. And I think we'll begin to see a resumption to normal."
Margins: Peak Quarter, Reinvestment Mandate
- Q3 gross margin: Reported at 65.5%, up 450 bps YoY, driven by product mix (more respiratory and higher-margin products), lower tender business, a forex tailwind, and the absence of COVID inventory provisioning taken in the prior quarter.
- Q4 moderation expected: Q3 is seasonally one of the best quarters of the year. Q4 margins will moderate with seasonality; US margins are expected to be higher than Q4 of the prior year but below Q3 levels.
- Full-year profitability: On track to deliver the guided 21–22% EBITDA margin range.
- Reinvestment posture: Management's stated intention is to grow margins year-on-year, but the pace will be measured because the objective is also to reinvest back in the business to grow faster. R&D spend is expected to inch up gradually from current levels and remain at ~6–7% of sales.
- Cost environment: Freight rates have moderated with further room to improve the air/sea mix. Procurement costs are showing stabilization, though the China supply situation is still evolving.
Vohra: "Our intention is to grow margins year-on-year. I think the pace of growth, as we've said earlier, that since we've reached the level of the 21% to 22% now, I think the objective is also to reinvest back in the business and to try and see if we can increase the margin profile further from here because we'd like to invest back to grow business faster."
Pipeline & Strategic Bets
- Respiratory assets: Clinical trials are ongoing on a respiratory asset (described only as "a product like Advair"), driving the increase in R&D spend. Filings on complex generics including peptide injectables remain on track.
- Advair: Responded to a minor query letter in the second review cycle; management feels closer to an approval, with a target action date in the first week of April.
- Abraxane: No new update; de-risking work continues. Potential launch is now seen in the later half of the second half of FY24.
- Biosimilars: Cipla initiated investment into a JV with Kemwell as the manufacturing partner during the quarter. Two products are in development, with one more selected to enter. Non-regulated market launches could occur in the next three to four years; regulated markets are five to six years out.
- Ethris GmbH partnership: Cipla took a minority stake to gain access to an inhaled-delivery platform for mRNA-based therapies, with the objective of bringing products into India.
- Point-of-care diagnostics: Identified as a nascent, future leg of the strategy to improve patient touch points; still at an early stage.
Capital Allocation: Surplus Cash, India-First M&A
- Cash position: The company is only in its second year of surplus cash and is evaluating options.
- M&A priorities: India is the highest priority for capital allocation given it remains a growth market. International and selective US opportunities are also on the radar.
- Capex: The capex program could increase in the next one to two years.
- Shareholder returns: The Board will discuss returning cash to shareholders via higher dividends or other means.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Advair approval | Target action date in first week of April; management feels closer to approval after responding to minor query in second review cycle | First week of April 2023 |
| US quarterly base | Guided to a base of about $185–190 mn | Q4 FY23 |
| Full-year EBITDA margin | In line with guidance of 21% to 22% | FY23 |
| R&D spend | Remain at ~6–7% of sales; absolute spend to inch up gradually | Ongoing |
| South Africa recovery | Worst is in the numbers; resumption to normal expected | Q1 FY24 |
| Complex US launches | Advair, Abraxane, one peptide product by September are the larger ones | Next 15 months |
| US revenue ambition | Reach $900 mn from current ~$700 mn 12-month run rate | Over a period of time |
| Biosimilars (non-regulated markets) | Potential launches | Next 3–4 years |
| Biosimilars (regulated markets) | Potential launches | 5–6 years out |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue | ₹5,810 cr, +6% YoY reported; +11% YoY COVID-adjusted |
| EBITDA margin | 24%+, +13% YoY reported EBITDA growth; +24% YoY COVID-adjusted |
| Gross margin | 65.5%, +450 bps YoY, driven by new launches and mix change |
| R&D spend | ₹363 cr (6.2% of revenue), +₹100+ cr YoY |
| Profit after tax (reported) | ₹801 cr (13.8% of sales), includes one-time deferred tax asset reversal |
| Profit after tax (adjusted) | ₹876 cr (15.1% of sales), +20% YoY adjusted growth |
| One India core portfolio growth | +11% YoY, COVID-adjusted; seventh consecutive quarter of market-beating growth |
| US core formulation sales | $195 mn, highest ever quarterly revenue, +30% YoY |
| Lanreotide market share | 14.1%, as of Nov '22 end; on track for 15% guidance |
| Albuterol market share | 18%, as per IQVIA week ending Dec 31, 2022 |
| Arformoterol market share | 39%, as per IQVIA week ending Dec 31, 2022 |
| India consumer franchise growth | +14% YoY, INR terms, adjusted for Q2 FY23 acquisition |
| Global consumer franchise share | ~9% of overall Cipla revenue |
| Chronic share of One India Rx | 60% of mix, expanded 240 bps YoY |
| Brands >₹100 cr (trailing 12M) | 21 brands, vs 19 in the corresponding previous period |
| Return on capital employed | 19.7%, trailing 12 months; tracking closer to 20% |
| South Africa private market share | 7.7%, third market position |